Venous Thromboembolism Risk in Hematological Malignancies Post-Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Meta-Analysis of Phase 2 and Phase 3 Clinical Trials

Chimeric Antigen Receptor T-cell (CAR-T) therapy uses genetically engineered T-cells with specific binding sites. This therapy allows for tumor specificity and durable treatment responses for patients with hematological malignancies. In this review, we study the risk of venous thromboembolism (VTE)...

Full description

Bibliographic Details
Published in:Current Oncology
Main Authors: Akshit Chitkara, Sushanth Sreenivasan, Yue Yin, Maitreyee Rai, Santhosh Sadashiv
Format: Article
Language:English
Published: MDPI AG 2024-07-01
Subjects:
Chimeric Antigen Receptor T-cell (CAR-T)
venous thromboembolism
meta-analysis
hematological malignancies
mantle cell lymphoma
B-cell lymphoma
Online Access:https://www.mdpi.com/1718-7729/31/8/323

Internet

https://www.mdpi.com/1718-7729/31/8/323

Similar Items